TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Adagene Inc.
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.

Insights
ADAG   positive

Advancing clinical trial, positive preliminary data, FDA alignment, and potential for novel cancer therapy